Key insights
- BD (BDX) partners with Wellstar to implement AI-powered medication systems. The integration of BD's Pyxis Pro and Alaris Infusion Systems aims to improve medication management and reduce waste. While positive for BD, the direct impact on the broader US equity market is limited, but it signals continued investment in healthcare technology.
FRANKLIN LAKES, N.J. and MARIETTA, Ga. - BD (NYSE:BDX) announced today a partnership with Wellstar Health System to implement medication dispensing and infusion technologies across the Georgia healthcare system’s hospitals and care facilities. The $41.66 billion medical technology company is a prominent player in the Healthcare Equipment & Supplies industry.
The collaboration involves integrating BD’s Pyxis Pro medication dispensing technologies with BD Alaris Infusion Systems, according to a press release statement. Wellstar will deploy the BD Pyxis Pro Dispensing Solution with Analytics in BD Incada, which uses artificial intelligence to provide visibility into medication inventory through natural-language queries.
The system includes customizable dashboards designed to help clinicians track medication availability and reduce waste. BD Alaris EMR Interoperability allows clinicians to use barcode scanning to send infusion orders directly from electronic medical records and receive infusion statuses back into the EMR.
"At Wellstar, our focus is on delivering safe, innovative care to every patient, every time," said Susan Wright, Pharm.D., Vice President, Pharmacy Services at Wellstar Health. "Partnering with BD to implement this technology strengthens our ability to focus on patient-centered programs and empower our teams to deliver care with confidence and compassion."
Wellstar participates on the Strategic Development Council for BD’s Medication Management Solutions business, where Wellstar leaders provide input on enterprise pharmacy operations, medication safety, nursing, and informatics.
BD is a medical technology company with over 60,000 employees operating globally, generating $21.92 billion in revenue over the last twelve months. Trading at a P/E ratio of 23.99, InvestingPro analysis indicates the stock is currently undervalued relative to its Fair Value, placing it among opportunities on the Most Undervalued list. The company has raised its dividend for 55 consecutive years, currently yielding 2.87%. For deeper insights, investors can access BD’s comprehensive Pro Research Report, one of 1,400+ available on InvestingPro. Wellstar Health System is a non-profit healthcare system in Georgia with 34,000 team members.
In other recent news, Becton Dickinson announced the commercial launch of the BD CentroVena One Insertion System, the first all-in-one central venous catheter insertion device available in the market. This new system integrates essential components like the introducer needle, syringe, guidewire, and catheter into a single platform, aiming to simplify central line placement procedures in the U.S. Additionally, the company declared a quarterly dividend of $1.05 per share, with an annual rate of $4.20 per share, payable on June 30, 2026.
The company also received CE Mark approval for its Liverty TIPS Stent Graft, allowing for its commercialization across the European Union. This device is designed to treat complications from portal hypertension in patients with cirrhosis. In analyst news, Evercore ISI reinstated coverage of Becton Dickinson with an Outperform rating, setting a price target of $180, while Argus lowered its price target from $230 to $180, citing market turbulence but maintaining a Buy rating. Both firms have noted the company’s strategic focus on growth opportunities in its Medical and Interventional segments following the divestiture of its Biosciences and Diagnostics business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.